Floatz logo

rg4733

Acral Lentiginous Malignant Melanoma

National Cancer Institute (NCI)Phase 2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Acral Lentiginous Malignant Melanoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Yonsei University
Phase 2BB
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B
Rivoceranib
Peking University Cancer Hospital & Institute
Phase 3B
Nilotinib
Institute of Cancer Research, United Kingdom
Phase 2B
Imatinib
National Cancer Institute (NCI)
Phase 2B

View all 29 →

Same molecule, other indications

rg4733 is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
melanomaDormant
CCC
Indicative ·
51 / 100
View asset →
Stage IV Skin MelanomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →